Sunzen Group Berhad (“Sunzen” or “the Group”), formerly known as Sunzen Biotech Berhad and an established player in Malaysia’s health products, medical devices and services, and loan financing with a diversified portfolio, today announced its unaudited financial results for the third quarter ended 31 March 2025 (“Q3 FY2025”), posting revenue of RM15.69 million and pre-tax profit of RM1.92 million. The performance was primarily driven by steady contributions from the loan financing and medical devices and services segments, reflecting the Group’s continued strategic repositioning following the recent signing of a Sale and Purchase Shares Agreement (“SPA”) to divest its non-core animal health operations.
As a result of the Group’s financial year-end change, there are no directly comparable figures for the corresponding quarter in the previous financial year.
Quarter-on-quarter (“QoQ”), revenue declined from RM27.35 million in Q2 FY2025, while pre-tax profit moderated from RM2.89 million to RM1.92 million. The decline was attributed to the normalisation of human health segment sales following festive-driven demand in the previous quarter, and the temporary suspension of edible bird’s nest exports to China due to Newcastle disease alerts. Export activities resumed in mid-January 2025, following the lifting of restrictions by the Department of Veterinary Services.
For the cumulative nine months ended 31 March 2025 (“9M FY2025”), Sunzen registered RM66.00 million in revenue and RM5.68 million in pre-tax profit, reflecting a profitable turnaround post-business restructuring. Notably, the loan financing segment contributed RM10.00 million in revenue and RM9.02 million in pre-tax profit during the period, underscoring its position as a stable earnings anchor for the Group.
The human health division, which includes bird’s nest, traditional Chinese medicine, and nutraceutical products, recorded revenue of RM9.68 million in the current quarter and RM48.29 million for the year-to-date (“YTD”). However, the segment incurred a pre-tax loss of RM0.56 million in Q3 and RM0.69 million YTD, impacted by softer market sentiment and the aforementioned export disruption to China.
The medical devices and services segment, driven by the Group’s acquisition of Eye Nation Medical Sdn. Bhd. in October 2024, delivered revenue of RM2.48 million and a pre-tax profit of RM0.42 million in the quarter. Year-to-date, the segment generated RM4.92 million in revenue and RM0.83 million in profit, reflecting growing traction from its ophthalmic product line and clinical support services to hospitals and private eye care facilities.
Meanwhile, the animal health segment, which was signed the SPA as at February 2025, recorded nil revenue and a pre-tax loss of RM1.11 million in Q3 FY2025. Its year-to-date contribution stood at RM2.80 million in revenue and RM3.49 million in cumulative losses.
Group Managing Director of Sunzen Group Berhad, Mr. Teo Yek Ming said, “Our performance this quarter reflects the resilience of our core businesses amid normalisation in consumer demand. While the human health segment faced temporary export disruptions, our expanding medical devices and services division and recurring income from loan financing have provided earnings stability. We continue to see strong momentum in the ophthalmic space and SME lending market.”
He added, “Following the signing of the divestment agreement for our non-core businesses, we are now fully focused on enhancing the scalability and integration of our remaining segments. With proceeds from the disposal, we are in a solid position to invest in working capital, product expansion, and further acquisition-led growth.”
Looking ahead, Sunzen remains cautiously optimistic. The Group will continue to strengthen its position in high-growth verticals, particularly medical devices and services and loan financing, while exploring alternative export avenues for its health portfolio in view of weaker China demand. Ongoing efforts to expand into original design manufacturing (“ODM”) and participation in global trade fairs are expected to support future growth initiatives.
